Cyberknife Global Market Report 2024

The cyberknife market has grown rapidly in recent years. It will grow from $0.55 billion in 2023 to $0.64 billion in 2024 at a compound annual growth rate (CAGR) of 17.7%. The expansion observed in the historical period can be attributed to several factors, including an increase in cancer incidence, a growing aging population, the rising demand for precision medicine, a preference among patients for non-invasive procedures, and advancements in the field of radiotherapy.

The cyberknife market is expected to see rapid growth in the next few years. It will grow to $1.16 billion in 2028 at a compound annual growth rate (CAGR) of 16.0%. The anticipated growth in the forecast period can be attributed to a global increase in the burden of cancer, advancements in oncology research, improved access to healthcare services, heightened awareness and education about cancer, and the integration of multidisciplinary approaches in cancer treatment. Key trends expected in the forecast period encompass the increased integration of proton therapy, a shift towards outpatient and freestanding treatment centers, a focus on patient-centric treatment planning, the growth of clinical evidence and research, and the adoption of telemedicine and remote treatment planning.

The anticipated growth in the cyberknife market is driven by the increasing incidence of cancer, a severe disorder characterized by rapid and uncontrolled cell reproduction leading to abnormal growth. CyberKnife, approved for the treatment of various cancers, presents a non-invasive and pain-free alternative in cases where radiation therapy is recommended. Ongoing research and development efforts aimed at enhancing the CyberKnife system and expanding its applications to address additional medical conditions are expected to contribute to the market's growth. For instance, as reported by ABC News Internet Ventures in January 2022, the projected number of newly diagnosed cancer cases in 2022 is around 2 million, representing a significant increase compared to the 1 million new cases reported in 2021. The escalating incidence of cancer, with approximately 5,250 new cases diagnosed daily in the United States, underscores the driving force behind the growth of the cyberknife market.

The growth of the cyberknife market is further propelled by the increasing preference for non-invasive or minimally invasive procedures. Minimally invasive interventions involve medical procedures that cause minimal disruption to the body's normal structures. CyberKnife, as a robotic radiosurgery system, offers several advantages in minimally invasive procedures, including precise tumor targeting, adaptability to moving targets, a reduced number of treatment sessions, enhanced patient comfort, and more. According to The American Society of Plastic Surgeons (ASPS) data in September 2023, approximately 23.7 million cosmetic minimally invasive procedures were performed in 2022. Specifically, the number of minimally invasive procedures involving Neuromodulator Injections surged by 73% from 2019, reaching approximately 8,736,591 procedures in 2022. This substantial growth in minimally invasive procedures highlights the increasing preference for such approaches and their contribution to the growth of the cyberknife market.

Prominent players in the cyberknife market are actively focusing on the development of innovative solutions, particularly in the realm of treatment planning systems. A treatment planning system (TPS) is a software platform utilized in radiation therapy and medical imaging to plan and optimize the delivery of radiation treatment to patients. Notably, Accuray Incorporated, a leading US-based manufacturer of radiation therapy systems, launched the 'RayStation' treatment planning support in June 2021. This solution is specifically tailored to support the CyberKnife M6 and S7 robotic and radiotherapy systems. RayStation facilitates clinicians in generating treatment plans for CyberKnife M6 and S7 Systems, along with other conventional radiation therapy devices, all within a unified treatment planning system. This initiative streamlines the integration of Accuray systems into radiation oncology departments, offering a cohesive and efficient planning solution.

Major players in the cyberknife market are directing their efforts towards the development of online adaptive therapy solutions. Online adaptive therapy involves a dynamic and real-time approach to treatment planning and delivery in radiation therapy. For instance, in October 2023, Accuray Incorporated introduced 'Cenos,' an online adaptive therapy option specifically designed for the Radixact System. Cenos empowers medical care teams to swiftly and effectively modify a treatment plan if necessary while the patient is still on the treatment table. Its integration enables Accuray customers to conduct online adaptation of treatment plans, accommodating changes that may arise between treatment sessions.

In September 2022, Standard Imaging, a US-based provider of quality assurance solutions in radiation therapy, acquired Integrated Medical Technologies (IMT) to enhance its offerings and market reach. This acquisition aims to better serve IMT's customer base by integrating complementary solutions, expanding production capabilities, and broadening market segments, particularly in tissue-equivalent dosimetry phantoms. Integrated Medical Technologies (IMT), a US-based company specializing in radiation therapy and medical imaging phantoms for both radiotherapy and diagnostic applications, aligns with Standard Imaging's objectives to provide comprehensive solutions in the radiation therapy domain.

Major companies operating in the cyberknife market report are Accuracy Inc., IBA Group, Mitsubishi Electric Corporation, Hitachi America Ltd., Sumitomo Heavy Industries Ltd., Nucletron B.V., General Electric Company, Varian Medical Systems Inc., RaySearch Laboratories AB, Brainlab AG, Nordion Inc., Modus Medical Devices Inc., Toshiba Medical Systems Corporation, ShenZhen Gene MDx Biotech Co. Ltd., ViewRay Inc., Mevion Medical Systems Inc., Isoray Inc., Optivus Proton Therapy Inc., Masep Medical Company, Best Medical International Inc., Huiheng Medical Inc., Cyber Medical Corporation, Siemens AG, Sun Nuclear Corporation, Koninklijke Philips N.V., CyberKnife Center of Miami, ALASKA CyberKnife Center, Elekta AB, RefleXion Medical Inc., ZAP Surgical Systems Inc., AccuBoost, Bionix Radiation Therapy LLC, C-RAD Co., Xcision Medical Systems LLC.

North America was the largest region in the cyberknife market in 2023. The regions covered in the cyberknife market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cyberknife market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary categorizations of the CyberKnife system include linear accelerator-based and standalone CyberKnife models. Linear accelerator-based CyberKnife refers to a system incorporating a linear accelerator (linac) directly onto a robotic platform for the delivery of high-energy photons or X-rays essential for radiation therapy. This specific type of CyberKnife device utilizing a linear accelerator is employed to administer precise and high-energy X-rays or photons for radiation therapy applications. CyberKnife systems find extensive use in healthcare settings such as hospitals, clinics, ambulatory surgical centers, and radiotherapy facilities. They serve as integral tools for treating tumors, cancer, vascular malformations, and various other medical conditions, providing a sophisticated and non-invasive approach to radiation therapy.

The cyberknife market research report provides cyberknife market statistics, including cyberknife industry global market size, regional shares, competitors with a cyberknife market share, detailed cyberknife market segments, market trends, and opportunities, and any further data you may need to thrive in the cyberknife industry. This cyberknife market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cyberknife market consists of sales of robotic linac, robotic manipulator, image guidance system, image tracking system. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.